BR112015023621A8 - derivados de meropenem e suas utilizações - Google Patents

derivados de meropenem e suas utilizações

Info

Publication number
BR112015023621A8
BR112015023621A8 BR112015023621A BR112015023621A BR112015023621A8 BR 112015023621 A8 BR112015023621 A8 BR 112015023621A8 BR 112015023621 A BR112015023621 A BR 112015023621A BR 112015023621 A BR112015023621 A BR 112015023621A BR 112015023621 A8 BR112015023621 A8 BR 112015023621A8
Authority
BR
Brazil
Prior art keywords
meropenem
derivatives
meropenem derivatives
Prior art date
Application number
BR112015023621A
Other languages
English (en)
Other versions
BR112015023621A2 (pt
Inventor
Popov Alexey
M Enlow Elizabeth
Chen Hongming
Bourassa James
Kim Jinsoo
Wojciech Nowak Pawel
Zapanta Ong Winston
Cu Yen
Original Assignee
Kala Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kala Pharmaceuticals Inc filed Critical Kala Pharmaceuticals Inc
Publication of BR112015023621A2 publication Critical patent/BR112015023621A2/pt
Publication of BR112015023621A8 publication Critical patent/BR112015023621A8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015023621A 2013-03-15 2014-03-14 derivados de meropenem e suas utilizações BR112015023621A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789335P 2013-03-15 2013-03-15
PCT/US2014/028627 WO2014144285A1 (en) 2013-03-15 2014-03-14 Meropenem derivatives and uses thereof

Publications (2)

Publication Number Publication Date
BR112015023621A2 BR112015023621A2 (pt) 2017-07-18
BR112015023621A8 true BR112015023621A8 (pt) 2018-01-23

Family

ID=51537664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023621A BR112015023621A8 (pt) 2013-03-15 2014-03-14 derivados de meropenem e suas utilizações

Country Status (8)

Country Link
US (4) US9725451B2 (pt)
EP (1) EP2968274B1 (pt)
JP (2) JP2016517435A (pt)
AU (2) AU2014227737B2 (pt)
BR (1) BR112015023621A8 (pt)
CA (1) CA2906689A1 (pt)
HK (1) HK1219233A1 (pt)
WO (1) WO2014144285A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111362239B (zh) * 2020-03-20 2021-07-06 辽宁瑞鸥新材料科技有限公司 一种用于铝硅系合金半固态制浆的Cs2HPO4气溶胶及其使用方法
CN112076161B (zh) * 2020-08-07 2022-10-18 安徽康正康仁药业有限公司 一种头孢菌素类钠盐与丙磺舒钠组成的复方冻干制剂
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2022231998A1 (en) * 2021-04-27 2022-11-03 Theaprin Pharmaceuticals, Inc. Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA84584B (en) * 1983-01-28 1984-09-26 Bristol Myers Co Substituted vinyl cephalosporins
EP0130119B1 (en) * 1983-06-23 1988-11-09 Merck & Co. Inc. (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives
US4914091A (en) 1984-04-02 1990-04-03 American Cyanamid Company Esters of cephalosporin derivitives
JPS6247874A (ja) 1985-08-27 1987-03-02 Sankyo Seiki Mfg Co Ltd プログラム動作装置の初期化方法
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
EP0910351A1 (en) * 1996-06-27 1999-04-28 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
KR100589030B1 (ko) 1998-05-01 2006-06-13 교토 야쿠힝 고교 가부시키가이샤 카르바페넴 유도체, 그 사용 방법 및 그 중간체 화합물
JP2000344773A (ja) * 1998-07-17 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、およびその用途並びにその中間体化合物
JP2000344772A (ja) 1998-05-01 2000-12-12 Kyoto Pharmaceutical Industries Ltd カルバペネム誘導体、その用途およびその中間体化合物
MXPA03010607A (es) 2001-05-21 2004-04-02 Kyoto Pharma Ind Compuesto de carbapenem.
US20050065141A1 (en) 2003-07-31 2005-03-24 Odink Debra A. Carbapenems useful in treating and preventing pulmonary infections, pharmaceutical compositions thereof and modes of administration thereof
EP2085084A1 (en) 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
EP2638007A2 (en) * 2010-11-11 2013-09-18 Redx Pharma Limited Drug derivatives
CA2858787C (en) * 2011-12-15 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of tertiary amine compounds
NZ742004A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport

Also Published As

Publication number Publication date
EP2968274A1 (en) 2016-01-20
AU2014227737A1 (en) 2015-10-08
AU2018203005A1 (en) 2018-05-17
JP6738918B2 (ja) 2020-08-12
AU2014227737B2 (en) 2018-05-17
US9725451B2 (en) 2017-08-08
US20160039823A1 (en) 2016-02-11
JP2019089829A (ja) 2019-06-13
EP2968274A4 (en) 2016-08-24
EP2968274B1 (en) 2019-10-16
HK1219233A1 (zh) 2017-03-31
US11091487B2 (en) 2021-08-17
CA2906689A1 (en) 2014-09-18
WO2014144285A1 (en) 2014-09-18
US20170349590A1 (en) 2017-12-07
US10392388B2 (en) 2019-08-27
JP2016517435A (ja) 2016-06-16
US20200010470A1 (en) 2020-01-09
US20210332048A1 (en) 2021-10-28
BR112015023621A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
BR302014000302S1 (pt) Configuração aplicada em pneumático
BR302013006428S1 (pt) Configuração aplicada em pneumático
BR302013005076S1 (pt) Configuração aplicada em pneumático
BR302013003723S1 (pt) Configuração aplicada em pneumático
DK3385545T3 (da) Forbindelsesorgan
BR302013005965S1 (pt) Configuração aplicada em otomana
BR302013005487S1 (pt) Configuração aplicada em aumotóvel
DK3087076T3 (da) Imidazopyrazinonderivater
HK1219233A1 (zh) 美羅培南衍生物及其用途
BR302013005862S1 (pt) Configuração aplicada em coador
TH1401007245B (th) ผลิตภัณฑ์ดูดซับ
TH146512B (th) ผลิตภัณฑ์ซึมซับ
UY4372S (es) Configuración aplicada en embalaje
FR3010330B1 (fr) Broyeur de vegetaux
BR302013001974S1 (pt) Configuração aplicada em pnemático
ES1079187Y (es) Babero perfeccionado
BR302013005268S1 (pt) Configuração aplicada em muleta axilar
UA25711S (uk) Серветка
BR302013004044S1 (pt) Configuração aplicada em macação
BR302013006223S1 (pt) Configuração aplicada em gabarito
BR302013002722S1 (pt) Configuração aplicada em longarina
TH1501001758A (th) ผลิตภัณฑ์ซึมซับ
BR302013002387S1 (pt) Configuração aplicada em volate
BR302013004984S1 (pt) Configuração aplicada em tamanco
BR302013003650S1 (pt) Configuração aplicada em campímetro

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements